



Agenda - Enpr-EMA Coordinating Group & networks meeting

Date: 2 March 2021; 14:00-15:30 CEST; By Adobe Connect

Chairpersons: Pirkko Lepola / Gunter Egger

 Agenda	Topic leader		Time
OPEN SESSION (all networks and observers)			
Adoption of agenda	Pirkko Lepola	For adoption	5′
Welcome to new members of coordinating group (CG): Andrea Braun-Scherhag (EUCOPE)	Gunter Egger	For information	5′
 Brief Updates from the working groups (WG): WG on ethics WG on research staff WG on international collaboration Clinical practice evidence in the labelling 	Gunter Egger Pirkko Lepola Pamela Dicks Thierry Lacaze Saskia de Wildt	For information and discussion	20'
Update from networks on mitigating impact of pandemic on clinical trial activities, business continuity planning Discussion on • whether new results from surveys on lessons learnt are available/published; how to consolidate the findings/recommendations and build on them	Pirkko Lepola Thierry Lacaze / Mark Turner / Regis Hankard / all	For discussion	20'
Information about paediatric COVID-19 - vaccine development and trial status	Gunter Egger Laura Fregonese	For discussion	25′

Official addressDomenico Scarlattilaan 61083 HS AmsterdamThe NetherlandsAddress for visits and deliveriesRefer to www.ema.europa.eu/how-to-find-usSend us a questionGo to www.ema.europa.eu/contactTelephone +31 (0)88 781 6000



An agency of the European Union

© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged.

Agenda	Topic leader		Time
АОВ	Gunter Egger	For information	5′
EU review – medicines for children & rare diseases			
Next meeting			
CLOSED SESSION (without industry observers)			
Enpr-EMA network membership criteria and proposal to simplify categorisation	Gunter Egger	For adoption	10'
	Pirkko Lepola		
End of meeting	Pirkko Lepola		